EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Early U.S. Real-World Experience With a Novel Intra-Annular Self-Expanding Valve for Transcatheter Aortic Valve Replacement

Santiago Garcia, Ibrahim Sultan, William Rollefson, Brandon M Jones, Rishi Puri, Amar Krishnaswamy, Gilbert H L Tang, Sahil Khera, Hemal Gada, Mathew Williams, Atman P Shah, Deepak Talreja und 2 weitere

JACC: Cardiovascular Interventions · 2026-04 · 19 (7) · 801-809

DOI: 10.1016/j.jcin.2025.10.053 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2026-04. Verfasst von Santiago Garcia und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Christ Hospital Network and Lindner Center for Research and Education, Cincinnati, Ohio, USA. Electronic address: santiagogarcia@me.com. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Aortic Valve Stenosis, Aortic Valve, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: A novel intra-annular, self-expanding transcatheter heart valve was introduced in the U.S. market in 2023 for treating native aortic stenosis in high- or extreme-risk patients. OBJECTIVES: The authors sought to report early real-world experience with the Navitor valve (Abbott Structural Heart) from the STS/ACC TVT Registry (Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry). METHODS: Baseline, procedural, and follow-up data were prospectively collected and retrospectively analyzed. The primary outcome was a composite of all-cause mortality or stroke at 30 days. Additional safety and effectiveness outcomes were reported per registry definitions. RESULTS: A total of 2,958 aortic stenosis patients were treated between January 2023 and December 2024. Mean age was 81.4 ± 7.6 years; 62.4% were female. Mean STS score was 6.6% ± 5.4%. Technical success rate was 97.9%, with in-hospital mortality rate at 1.3%. Thirty-day all-cause mortality or stroke rate was 5.2% (2.8% mortality, 2.7% stroke). Major vascular complications and new permanent pacemaker implantation (PPI) occurred in 1.8% and 17.8%, respectively. At 30 days, mean transvalvular gradient was 7.3 ± 3.8 mm Hg; aortic valve area was 1.98 ± 0.64 cm2; moderate or greater PVL occurred in 1.8%. Analysis of case volume showed reduced PPI rate with site experience beyond 20 cases for Navitor Classic (19.4% vs 13.5%; P = 0.0039) and Vision (19.1% vs 10.6%; P = 0.047). Kansas City Cardiomyopathy Questionnaire Overall Summary score improved by 23.8 points from 52.1 ± 24.8 at baseline to 75.9 ± 22.6 at 30 days (P < 0.0001). CONCLUSIONS: Early U.S. experience with the Navitor valve demonstrates favorable early clinical and hemodynamic outcomes, with improved PPI rate associated with procedural experience.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve ProsthesisAortic Valve StenosisAortic ValveTranscatheter Aortic Valve ReplacementHumansFemaleTreatment OutcomeTime FactorsAged, 80 and overProsthesis DesignRegistriesRisk FactorsRetrospective StudiesAgedMaleRecovery of FunctionUnited StatesRisk AssessmentHospital MortalityHemodynamicsStroke

Stichwörter der Autor:innen

Navitoraortic stenosisdegenerative valveelderlyquality of lifetranscatheter aortic valve replacement

Autor:innen und Institutionen

  • The Christ Hospital Network and Lindner Center for Research and Education, Cincinnati, Ohio, USA. Electronic address: santiagogarcia@me.com.
  • UPMC Presbyterian, Pittsburgh, Pennsylvania, USA.
  • Arkansas Heart Hospital, Little Rock, Arkansas, USA.
  • Providence-St. Vincent, Portland, Oregon, USA.
  • Cleveland Clinic, Cleveland, Ohio, USA.
  • Mount Sinai Health System, New York, New York, USA. Electronic address: https://twitter.com/GilbertTangMD.

Zitieren

APA

Garcia, S., Sultan, I., Rollefson, W., Jones, B. M., Puri, R., Krishnaswamy, A., Tang, G. H. L., Khera, S., Gada, H., Williams, M., Shah, A. P., Talreja, D., Yadav, P., & Thourani, V. (2026). Early U.S. Real-World Experience With a Novel Intra-Annular Self-Expanding Valve for Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 19(7), 801-809. https://doi.org/10.1016/j.jcin.2025.10.053

Vancouver

Garcia S, Sultan I, Rollefson W, Jones BM, Puri R, Krishnaswamy A, et al. Early U.S. Real-World Experience With a Novel Intra-Annular Self-Expanding Valve for Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions. 2026;19(7):801-809. doi:10.1016/j.jcin.2025.10.053

BibTeX
@article{Garcia2026,
  author = {Garcia, Santiago and Sultan, Ibrahim and Rollefson, William and Jones, Brandon M and Puri, Rishi and Krishnaswamy, Amar and Tang, Gilbert H L and Khera, Sahil and Gada, Hemal and Williams, Mathew and Shah, Atman P and Talreja, Deepak and Yadav, Pradeep and Thourani, Vinod},
  title = {Early U.S. Real-World Experience With a Novel Intra-Annular Self-Expanding Valve for Transcatheter Aortic Valve Replacement},
  journal = {JACC: Cardiovascular Interventions},
  year = {2026},
  volume = {19},
  number = {7},
  pages = {801--809},
  doi = {10.1016/j.jcin.2025.10.053}
}
Kostenlos starten →